Clinical Registries Need Streamlining To Reap Benefits, Mussallem Tells Congress
This article was originally published in The Gray Sheet
Clinical registries can yield useful information on patient outcomes that can support approval, reimbursement and care decisions but the benefits of registries need to be balanced against their costs, Edwards Lifesciences CEO Michael Mussalem told a House Energy and Commerce subcommittee July 22.
You may also be interested in...
Electronic health records would have to be coordinated enough for users to view results of patient tests, see registry information, and access device data under a Senate HELP Committee draft bill calling for federal standards, but health IT groups say they would prefer a more voluntary approach.
A clinical registries bill passed by the House Energy and Commerce Committee July 30 would call on HHS to recommend how to tie data from patients’ electronic health records into information collected from clinical trials, and on ways to use registries to capture postmarket device data and support device reimbursement.
Incorporating unique device identifiers into insurance claims is necessary to leverage FDA’s Sentinel postmarket surveillance initiative to devices, Josh Rising of The Pew Charitable Trusts emphasized to House lawmakers at a recent hearing.